S&P 500 Healthcare Sector SEC Filings — July 23, 2026

23-07-2026

Thermo Fisher Scientific reported strong Q2 2026 results with revenue growing 10% to $11.99B, driven by 5% organic growth. GAAP diluted EPS grew 9% to $4.68 and adjusted EPS grew 13% to $6.03. However, net income margin attributable to the company slightly declined to 14.5% from 14.9% in the prior year quarter, and the company announced the divestiture of its microbiology business.

• · Revenue growth included 5% from acquisitions and 1% from currency translation, with organic growth at 5%.
• · GAAP operating margin improved to 17.4% from 16.9% in Q2 2025.
• · Adjusted operating margin improved to 22.8% from 21.9% in Q2 2025.
• · Free cash flow increased 52% YoY to $1.68B.
• · Company repurchased $1.0B of stock during the quarter.
• · Company announced divestiture of its microbiology business.
• · All four business segments reported revenue growth: Life Sciences Solutions +12.6%, Analytical Instruments +6.9%, Specialty Diagnostics +6.3%, Laboratory Products and Biopharma Services +11.6%.
• · Segment income margins improved across all segments: Life Sciences Solutions 37.0% (vs 36.8%), Analytical Instruments 23.0% (vs 18.8%), Specialty Diagnostics 27.7% (vs 27.0%), Laboratory Products and Biopharma Services 14.0% (vs 13.8%).
• · Net income margin attributable to Thermo Fisher declined to 14.5% from 14.9% in Q2 2025.
• · Weighted average diluted shares decreased to 371M from 378M, reflecting share repurchases.

23-07-2026

Lilly Endowment, Inc. filed an amended Schedule 13G disclosing beneficial ownership of 90,376,978 shares of Eli Lilly & Co common stock as of June 30, 2026, representing 9.6% of the 941,741,406 shares outstanding. The filing reflects a routine ownership update with no change in the nature of the holding (all shares are directly owned, none acquired via options).

• · The filing is an amendment (Schedule 13G/A) filed under Rule 13d-1(d).
• · Lilly Endowment, Inc. is a Section 501(c)(3) private foundation organized under Indiana law.
• · No shares are deemed beneficially owned via a right to acquire; all 90,376,978 shares are directly held.
• · The filing date is July 23, 2026, with an as-of date of June 30, 2026.

23-07-2026

EVP, Chief Reg. & Quality Off. Tatsis Ourania was awarded 8,251 Common Stock. Tatsis Ourania holds 53,572 shares after the transaction.

• · EVP, Chief Reg. & Quality Off. Tatsis Ourania was awarded 8,251 Common Stock

23-07-2026

Johnson & Johnson reported Q2 2026 sales of $25.3B, up 6.6% YoY from $23.7B, with gross margin improving to 68.2% from 67.9%. However, net earnings for the quarter were essentially flat at $5.534B vs $5.537B, and diluted EPS declined to $2.27 from $2.29. For the six-month period, net earnings dropped 34.9% to $10.769B from $16.536B, largely due to a prior-year gain in Other income/expense. The company maintained a strong balance sheet with total assets of $201.1B and shareholders' equity of $85.0B.

• · Q2 2026 gross profit was $17.259B (68.2% of sales) vs $16.115B (67.9%) in Q2 2025.
• · Selling, marketing and administrative expenses rose to $6.432B (25.4% of sales) from $5.889B (24.8%).
• · Research and development expense increased to $3.653B (14.4% of sales) from $3.516B (14.8%).
• · Interest income decreased to $219M from $260M; interest expense net was $281M vs $308M.
• · Other (income) expense net was $331M expense in Q2 2026 vs $107M expense in Q2 2025.
• · Restructuring charges were $34M in Q2 2026 vs $64M in Q2 2025.
• · Provision for taxes on income was $1.213B (4.8% of sales) vs $954M (4.0%).
• · Cash dividends paid were $1.34 per share in Q2 2026, totaling $3.227B.
• · Share repurchases (including excise tax) were $219M in Q2 2026.
• · Total current assets increased to $59.774B from $55.624B at year-end 2025.
• · Total current liabilities were $54.895B vs $54.126B at year-end 2025.
• · Long-term debt decreased to $37.344B from $39.438B.
• · Accumulated other comprehensive loss improved to $(13.951)B from $(14.930)B.
• · In-process R&D impairments of $36M were recorded in H1 2026 vs nil in H1 2025.
• · Other (income) expense net for H1 2026 was $625M expense vs $(7.214)B income in H1 2025 (prior year included a large gain).

23-07-2026

Edwards Lifesciences reported Q2 2026 sales of $1.74 billion, up 13.6% YoY (12.5% constant currency), driven by strong TAVR growth of 11.3% to $1.26 billion and TMTT growth of 47.3% to $195.9 million. Adjusted EPS was $0.78, beating expectations, and the company raised its full-year constant currency sales growth guidance to 10%-11% from 9%-11%. However, gross profit margin remained flat at 77.5% due to FX headwinds, and the company now expects its effective tax rate to be at the high end of its 16%-19% range, partially offsetting the positive momentum.

• · Q2 adjusted EPS was $0.78, benefiting from better-than-expected topline and planned phasing of strategic investments.
• · Q2 GAAP EPS was $0.42.
• · Full-year adjusted EPS guidance reaffirmed at $2.95-$3.05 (17% growth at midpoint) despite higher expected tax rate.
• · Q3 2026 guidance: total sales $1.63-$1.71 billion, adjusted EPS $0.71-$0.77.
• · Cash and equivalents $2.9B, total debt $600M, $1.5B remaining under share repurchase authorization.
• · Gross margin expected at lower end of 78%-79% full-year guidance due to FX hedging impacts.
• · Operating margin expected at high end of 28%-29% guidance, ~150 bps constant currency expansion for full year.
• · Effective tax rate now expected at high end of 16%-19% range due to Pillar Two legislation delay and California R&D credit restrictions.
• · CMS final decision memo on TAVR NCD expected in September 2026.
• · Q4 2026 expected approvals: PASCAL tricuspid indication in U.S., next-gen PASCAL with Capture Clarity in U.S. and Europe, and CLASP IITR trial results at TCT.
• · Surgical segment grew 6.5% YoY, slower than TAVR and TMTT.
• · R&D spending decreased as a percentage of sales to 16.0% from 18.0% YoY, reflecting revenue growth and strategic prioritization.